Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

20.88 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report
Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE: CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid... 
Via Benzinga
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Friday Markets News
Methane leaks in the Permian Basin are 6 times higher than estimates. 
Via Talk Markets
Why Are Teva Pharmaceutical Shares Trading Higher Today?
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA)  
Via Benzinga
The Struggles Continue For Generic Drugs Behemoth Teva Pharmaceutical
Teva reported light fourth-quarter sales as its own generic drugs struggled and Copaxone sales tumbled. 
Via Investor's Business Daily
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
Rhode Island Announces $107M Opioid Settlements With Teva, Allergan: Reuters
Rhode Island's attorney general announced settlements worth $107 million against Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc's (NYSE: ABBV) Allergan unit to resolve claims over 
Via Benzinga
Lucky Day
Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund. 
Via Talk Markets
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill
Via Benzinga
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
Rhode Island's Opioid Trial Against Teva Begins Today: Reuters
The first trial in Rhode Island state court against Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) alleged responsibility for the opioid crisis begins jury... 
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters
Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Putin on the brink
For the first time in history, Swiss banks have penalized account owners for political actions and joined a SWIFT boycott. 
Via Talk Markets
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
A Receding tide
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient. 
Via Talk Markets
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
Global Cannabis Extract Market To Surpass $38B By 2030, Key Players Include Tilray, Canopy Growth, Aurora
According to Coherent Market Insights, the global cannabis extract market is estimated to be valu... 
Via Benzinga
Israeli Study Reveals Promising Medical Cannabis Results, Especially For PTSD Treatment
A recent clinical trial conducted by Soroka University Medical Center and Israeli medical cannabis company Cannbit-Tikun O... 
Via Benzinga
World Markets News For Monday
European markets were down over fear of Ukrainian battles. 
Via Talk Markets
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Inflation inflating
The Fed will be raising interest rates soon and this will chop the appeal of investments in more vulnerable yield plays. 
Via Talk Markets
Dampening Exuberance
The bond sell-off halted today but the Fed's plans mean this will resume. 
Via Talk Markets
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Teva Pharmaceutical: Q4 Earnings Insights
  Teva Pharmaceutical Industries (NYSE:TEVA) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.